# Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

> **NCT01172223** · PHASE1,PHASE2 · COMPLETED · sponsor: **Prof Dirk Elling** · enrollment: 81 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Myocet (Non-pegylated liposomal doxorubicin (NPLD))
- **DRUG:** Paclitaxel
- **DRUG:** Lapatinib (GW572016, Tykerb)

## Key facts

- **NCT ID:** NCT01172223
- **Lead sponsor:** Prof Dirk Elling
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-12
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01172223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01172223, "Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01172223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*